- Location
Genentech
"-
The FDA Won't Let 23andme Sell Its Personal Genomic Service Tests
Jan 12, 2015The FDA won’t let 23andMe sell its Personal Genomic Service tests to consumers in the United States, but that hasn’t stopped the company from selling its customers’ anonymous information to other companies for research. ...
-
CHMP Has Issued a Positive Opinion for The Use of Novartis' Xolair as an Add-on Therapy
Feb 10, 2014The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the use of Novartis’ Xolair (omalizumab) as an add-on therapy for the treatment of chronic spontaneous ...
-
Google Sent Several of Its Employees to Meet with Staff From FDA's Medical Device Branch
Jan 15, 2014Google recently sent several of its employees to meet with staff from FDA’s medical device branch. Bloomberg speculates that the new product could be tied to biosensors. The employees in question hail from the company’s Google ...
Tags: Medical Device, Google
-
The Liquid Form of The Flu Drug Tamiflu Is in Short Supply Because of Early Strong Demand
Jan 10, 2014The liquid form of the flu drug Tamiflu is in short supply because of early strong demand.But the shortage is expected to be brief, lasting only through mid-January, according to its manufacturer, Genentech. Doctors typically give the ...
Tags: Tamiflu, Tamiflu Shortage, Health News
-
Women with Aggressive Breast Cancer Have a Slightly Improved Chance of Staying Cancer-Free
Dec 27, 2013Women with aggressive breast cancer who receive combination targeted therapy with chemotherapy prior to surgery have a slightly improved chance of staying cancer-free, researchers say. However, the improvement was not statistically ...
Tags: aggressive breast cancer, targeted therapy with chemotherapy
-
Women Fighting an Aggressive Form of Breast Cancer May Benefit From Adding Certain Drugs
Dec 25, 2013Women fighting an aggressive form of breast cancer may benefit from adding certain drugs to their chemotherapy regimen, and taking them prior to surgery, new research finds. This pre-surgical drug therapy boosts the likelihood that no ...
-
Monoclonal Antibody Agents Have Been Successfully Used in The Treatment of Tumors
Dec 23, 2013Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the market size of monoclonal antibody agents ...
-
Ocera Therapeutics Has Entered Into a Technology Transfer and License Deal
Dec 20, 2013Ocera Therapeutics has entered into a technology transfer and license deal with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its Macrocyclic Template Chemistry (MATCH) ...
Tags: Ocera Therapeutics, License Deal
-
Ocera Therapeutics Has Entered Into a Technology Transfer and License Pact with Roche
Dec 19, 2013Ocera Therapeutics (Nasdaq:OCRX) today announced that it has entered into a Technology Transfer and License Agreement with the Roche Group, including the Research and Early Development arms of both Genentech and Roche, for rights to its ...
Tags: Ocera Therapeutics, Roche, Macrocyclic Template Chemistry
-
FDA Has Accepted and Filed The Company's Supplemental Biologics License Application
Oct 12, 2013Genentech, a member of the Roche Group, has announced that the US Food and Drug Administration (FDA) has accepted and filed the company's supplemental biologics license application (sBLA) for subcutaneous use of Xolair (omalizumab) in ...
-
Tracon Has Started Dosing in a Phase Ib Clinical of TRC105 for The Treatment of Patients
Sep 25, 2013US-based biopharmaceutical firm Tracon Pharmaceuticals has started dosing in a Phase Ib clinical of TRC105 for the treatment of patients with metastatic renal cell carcinoma. The trial evaluates the combination of TRC105 and a standard ...
Tags: Tracon, Carcinoma Drug
-
Adimab Signed a Multi-Target Discovery Agreement with Celgene Corporation
Aug 22, 2013Adimab signed a multi-target discovery agreement with Celgene Corporation, pursuant to which, Adimab will use its proprietary discovery and optimization platform to generate fully human antibodies against multiple targets. Under the terms ...
Tags: Adimab, Drug Discovery
-
Curis Has Obtained The Conditional Approval for Erivedge to Treat Adult Patients
Jul 17, 2013Oncology-focused drug development company Curis has obtained the conditional approval for Erivedge (vismodegib) to treat adult patients with symptomatic metastatic basal cell carcinoma (BCC) or locally advanced BCC inappropriate for surgery ...
-
FDA Has Cleared Gilotrif as a New Medication for Patients with Late Stage NSCLC
Jul 16, 2013The US Food and Drug Administration (FDA) has cleared Boehringer Ingelheim's tyrosine kinase inhibitor Gilotrif (afatinib) as a new medication for patients with late stage (metastatic) non-small cell lung cancer (NSCLC). The approval also ...
Tags: FDA, Lung Cancer Therapy, Medicine
-
Genentech Obtained FDA Priority Review Status for GA101 to Treat CLL
Jul 5, 2013Genentech, a member of the Roche Group, has obtained FDA priority review status for Obinutuzumab (GA101) to treat previously untreated chronic lymphocytic leukemia (CLL). The FDA has also accepted the company's biologics license ...
Tags: Genentech, FDA Priority